Zacks Investment Research upgraded shares of Concord Medical Services (NYSE:CCM) from a sell rating to a hold rating in a report released on Monday morning.
According to Zacks, “Concord Medical Services Holdings Limited operates a large network of radiotherapy and diagnostic imaging centers in China. Most of the centers in their network are established through long-term lease and management services arrangements entered into with their hospital partners. Under these arrangements, Concord Medical receives a contracted percentage of each center’s revenue net of specified operating expenses. Each center is located on the premises of their hospital partners and is typically equipped with a primary unit of advanced radiotherapy or diagnostic imaging equipment, such as a linear accelerator, head gamma knife system, body gamma knife system, PET-CT scanner or MRI scanner. “
Get Concord Medical Services alerts:
Separately, ValuEngine raised Concord Medical Services from a sell rating to a hold rating in a research report on Wednesday, May 2nd.
Shares of NYSE:CCM opened at $4.14 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 0.44. Concord Medical Services has a 52 week low of $2.46 and a 52 week high of $4.29.
Concord Medical Services Company Profile
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company's services comprise linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, CyberKnife robotic radiosurgery system, proton beam therapy systems, and diagnostic imaging services.
Get a free copy of the Zacks research report on Concord Medical Services (CCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com